Skip to main content

Spectrum: Autism Research News

Tag: Rett syndrome

October 2023
Illustration of a sheet of red and white pills, with the red pills arranged in the form of a question mark.

New template streamlines sharing clinical trial results

by  /  31 October 2023

This month’s Going on Trial newsletter explores a new tool for communicating with clinical trial participants and their families, among other drug development news.

Comments
August 2023
Illustration of a sheet of red and white pills, with the red pills arranged in the form of a question mark.

Trials test utility of EEG biomarkers for autism-related conditions

by  /  31 August 2023

This month’s Going on Trial newsletter dives into an electroencephalography biomarker that could track the efficacy of treatments for dup15q and Angelman syndromes, among other drug development news.

Comments
July 2023
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

How organ-on-a-chip models can help drug development

by  /  31 July 2023

This month’s Going on Trial newsletter explores how organ-on-a-chip models could smooth the transition from preclinical to clinical trials, among other drug development news.

Comments
June 2023
Illustration of a sheet of red and white pills, with the red pills arranged in the form of a question mark.

Going on Trial: Gene therapy for Rett; return to arbaclofen

by  /  29 June 2023

This month’s newsletter looks at the early safety data from the first gene therapy trial for Rett syndrome, among other drug development news.

Comments
April 2023
Illustration of a room with DNA sequence wallpaper and three doors leading to abstract new environments.

The future of autism therapies: A conversation with Lilia Iakoucheva and Derek Hong

by  /  14 April 2023

If a therapy for autism’s core traits makes it to market, it will likely take one of three forms, the researchers say.

Comments
March 2023
Drop of liquid medicine with air bubbles is dripping from a pipette on a light pink background.

FDA approval of trofinetide may spur further drug development for Rett

by  /  16 March 2023

The drug, welcomed by patients, might be just the first of many.

Comments
Illustration of a gloved hand reaching down to place a pill bottle on a pedestal.

Debut drug for Rett syndrome at edge of approval

by  /  2 March 2023

The U.S. Food and Drug Administration plans to make an approval decision on the first-ever drug for girls and women with Rett syndrome by 12 March.

Comments
February 2023
Illustration of a sheet of red and white pills, with the red pills arranged in the form of a question mark.

Going on Trial: Orphan drugs; CBD; bumetanide

by  /  28 February 2023

This month’s newsletter takes a close look at the orphan drug program in the United States, several cannabis-based therapies and a secondary analysis of bumetanide, among other new developments in autism-related drug trials.

Comments
Illustration of a series of pills in petri dishes laid out to look like a descending line graph.

Biotech downturn hurts companies targeting autism-linked conditions

by  /  23 February 2023

After a year of intense growth, funding for biotech is in decline. The result is layoffs and program cuts — and maybe some innovation.

Comments
Research image of cell bodies of rett-like neurons, some of which were treated with epigenome editors.

Epigenome edits unmute MECP2 in Rett-like neurons

by  /  16 February 2023

The approach removes methyl tags from the gene and shields it from other silencing factors without changing the gene itself, raising hopes for a new treatment.

Comments